Continue
NCCN Clinical Practice Guidelines in Oncology™
Dermatofibrosarcoma
Protuberans
V.1.2010
www.nccn.org
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
NCCN Dermatofibrosarcoma Protuberans Panel Members
* Stanley J. Miller, MD/Chair
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Murad Alam, MD
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University
James Andersen, MD
City of Hope
Comprehensive Cancer Center
Daniel Berg, MD
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance
Christopher K. Bichakjian, MD
University of Michigan
Comprehensive Cancer Center
Glen Bowen, MD
Huntsman Cancer Institute
at the University of Utah
Richard T. Cheney, MD
Roswell Park Cancer Institute
L. Frank Glass, MD
H. Lee Moffitt Cancer Center &
Research Institute
� �
� �
�
�
�
�
� �
¶
¶
¶
Kishwer S. Nehal, MD
Memorial Sloan-Kettering Cancer Center
Kelly C. Nelson, MD
Duke Comprehensive Cancer Center
Paul Nghiem, MD, PhD
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance
Thomas Olencki, DO
Arthur G. James Cancer Hospital &
Richard J. Solove Research Institute
at The Ohio State University
�
�
�
�
�
�
�
¶
¶
¶
¶
‡
Clifford S. Perlis, MD, MBe
Fox Chase Cancer Center
E. William Rosenberg, MD
St. Jude Children’s Research Hospital/
University of Tennessee Cancer Institute
Ashok R. Shaha, MD
Memorial Sloan-Kettering Cancer Center
Marshall M. Urist, MD
University of Alabama at Birmingham
Comprehensive Cancer Center
Linda C. Wang, MD, JD
Dana-Farber/Brigham and Women’s
Cancer Center
John A. Zic, MD
Vanderbilt-Ingram Cancer Center
�
�
�
Dermatology
¶ Surgery/Surgical oncology
Otolaryngology
Pathology/Dermatopathology
† Medical oncology
§ Radiotherapy/Radiation oncology
‡ Hematology/Hematology oncology
* Writing Committee Member
Continue
NCCN Guidelines Panel Disclosures
Roy C. Grekin, MD
UCSF Helen Diller Family
Comprehensive Cancer Center
Dennis E. Hallahan, MD
Siteman Cancer Center
at Barnes-Jewish Hospital and
Washington University
School of Medicine
Anne Kessinger, MD
UNMC Eppley Cancer Center at
The Nebraska Medical Center
Nancy Y. Lee, MD
Memorial Sloan-Kettering Cancer Center
Nanette Liegeois, MD, PhD
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Daniel D. Lydiatt, DDS, MD
UNMC Eppley Cancer Center at
The Nebraska Medical Center
Jeff Michalski, MD, MBA
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University
School of Medicine
William H. Morrison, MD
The University of Texas
M.D. Anderson Cancer Center
�
� �
¶
§
†
§
¶
¶
§
§
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
Table of Contents
NCCN Dermatofibrosarcoma Protuberans Panel Members
Summary of Guidelines Updates
Clinical Presentation, Preliminary Treatment, and Workup (DFSP-1)
Treatment and Follow-up (DFSP-2)
Excision (DFSP-A)
Guidelines Index
Print the Dermatofibrosarcoma Protuberans Guidelines
Dermatofibrosarcoma Protuberans
These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.
Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical
circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties
of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These
guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not
be reproduced in any form without the express written permission of NCCN. ©2010.
For help using these
documents, please click here
Discussion
References
Clinical Trials:
NCCN Categories of Evidence and
Consensus:
The
believes that the best management
for any cancer patient is in a clinical
trial. Participation in clinical trials is
especially encouraged.
To find clinical trials online at NCCN
member institutions,
All recommendations
are Category 2A unless otherwise
specified.
See
NCCN
click here:
nccn.org/clinical_trials/physician.html
NCCN Categories of of Evidence
and Consensus
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
Summary of the Guidelines updates
Summary of changes in the 1.2010 version of the Dermatofibrosarcoma Protuberans guidelines from the 1.2009 version include:
Footnote “d”; First sentence: “(180-200 cGy fractions per day)” changed to “( cGy fractions per day)”.� 200
( )DFSP-2
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
UPDATES
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CLINICAL PRESENTATION CLINICAL FINDINGS
Suspicious lesion
H&P
Complete skin exam
�
�
Biopsy
H&E
Immunopanel (eg, CD34, factor XIIIa)
Note and report evidence of
fibrosarcoma change
a
�
�
�
Inadequate
biopsy
Adequate
biopsy
Rebiopsya
PRELIMINARY TREATMENT
See Treatment
(DFSP-2)
aThis tumor is frequently misdiagnosed, even with multiple preliminary biopsies.
DFSP-1
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
Consider radiation
therapy
or
Imatinib mesylate
d
e Metastasis
Consider clinical
trial, imatinib
mesylate ,
chemotherapy, RT
or resection as
feasible, given the
specific clinical
circumstances
e
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
TREATMENT
Excisionb
Positive
surgical
margins
Positive
surgical
margins
Negative
surgical
margins
Negative
surgical
margins
Observe
or
Consider
adjuvant RTc,d
FOLLOW-UP
�
�
Check primary
site every 6-12
months
Patient
education about
regular self-exam
b
c
d
The surgical approach to DFSP must be meticulously planned. Size and location of the tumor and cosmetic issues will dictate the most appropriate surgical
procedure.
Consider postoperative radiation therapy for large lesions or if there is concern about adequacy of surgical margins.
5,000-6,000 cGy for close-to-positive or positive margins (200 cGy fractions per day). Fields to extend widely beyond surgical margin (eg, 3-5 cm), when clinically
feasible.
Tumors lacking the t(17;22) translocation may not respond to imatinib. Molecular analysis of a tumor using cytogenetics may be useful prior to the institution of
imatinib therapy.
e
See Excision (DFSP-A).
Re-resectionb
DFSP-2
Recurrence
Re-resection as
feasible
or
Consider RT if not
given previously
or
Imatinib mesylate
in cases where
unacceptable
functional or
cosmetic outcomes
will occur
e
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
DFSP Table of Contents
Discussion, ReferencesDermatofibrosarcoma Protuberans
Practice Guidelines
in Oncology – v.1.2010NCCN
®
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EXCISION
Goal:
Every effort should be made to achieve clear surgical margins. Tumor characteristics include
long, irregular, subclinical extensions.
Varied Approaches:
Mohs technique
Modified Mohs = Mohs technique with additional final margin for permanent section assessment.
CCPDMA= Complete circumferential and peripheral deep-margin assessment.
2-4 cm margins to investing fascia of muscle or pericranium with clear pathologic margins, when
clinically feasible.
Reconstruction:
Immediate reconstruction in most cases
It is preferable to delay reconstruction involving extensive undermining or flaps until negative
surgical margins are assessed and certified pathologically clear.
If there is concern that the surgical margins are not completely clear, avoid undermining and
consider split thickness skin grafting (STSG) to monitor for recurrence.
�
�
�
�
�
�
�
�
1
See the NCCN Soft Tissue Sarcoma Guideline for Principles of Sarcoma Surgery (SARC-C)
DFSP-A
1Mohs technique is used primarily in DFSP to insure complete removal and clear margins, and secondarily for its tissue sparing capabilities.
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. MS-1
Guidelines Index
DFSP Table of Contents
Discussion, References
Practice Guidelines
in Oncology – v.1.2010 Dermatofibrosarcoma Protuberans
®
NCCN
Discussion
NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence
(e.g. randomized controlled trials) and there is uniform NCCN
consensus.
Category 2A: The recommendation is based on lower-level evidence
and there is uniform NCCN consensus.
Category 2B: The recommendation is based on lower-level evidence
and there is nonuniform NCCN consensus (but no major
disagreement).
Category 3: The recommendation is based on any level of evidence
but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Overview
NCCN Non-Melanoma Skin Cancer Panel has developed these
guidelines outlining the treatment of dermatofibrosarcoma protuberans
(DFSP) to supplement their other guidelines (NCCN Basal Cell and
Squamous Cell Skin Cancers Guidelines and NCCN Merkel Cell
Carcinoma Guidelines). The NCCN Soft Tissue Sarcoma Panel
provided expert input in the development of DFSP guidelines. DFSP is
an uncommon, low-grade sarcoma of fibroblast origin with an incidence
rate of 4.2 to 4.5 cases per million persons per year in the United
States.1,2 It rarely metastasizes. However, initial misdiagnosis,
prolonged time to accurate diagnosis, and large tumor size at the time
of diagnosis is common. Three-dimensional reconstruction of DFSP3
has revealed tumors with highly irregular shapes and frequent
finger-like extensions.4 As a result, incomplete removal and subsequent
recurrence are common. The local recurrence rate for DFSP in studies
ranges from 0-60%, whereas the rate of development of regional or
distant metastatic disease is only 1% and 4-5%, respectively.5
Diagnosis
As with all solid tumors, clinical suspicion is confirmed by biopsy. In
most cases, examination of hematoxylin and eosin-stained specimens
by light microscopy results in an unequivocal diagnosis. However,
differentiation of DFSP from dermatofibroma can be difficult, at times. In
such instances, immunostaining with CD34, factor XIIIa,
metallothioneins, tenascin, and/or stromelysin-3 may be useful.5-9
Therefore, the panel recommends that appropriate and confirmatory
immunostaining be performed in all cases of suspected DFSP. Finally,
it is unclear whether the histologic features of a high mitotic rate or
evidence of fibrosarcomatous change (typically in more than 5% of the
surgical specimen) have prognostic significance in DFSP. Studies in
the biomedical literature both support10,11 and refute12 this notion. Thus,
the panel requested that these two features be noted in all pathology
reports assessing this tumor.
When the clinician’s suspicion for DFSP is high, but the initial biopsy
does not support the diagnosis, re-biopsy is recommended and may
reveal tumor presence. Multiple non-supportive or equivocal biopsies
over time, before definitive diagnosis, are common in the clinical history
for this tumor; thus, DFSP is frequently misdiagnosed. Because
metastatic disease is rare, an extensive workup is not routinely
indicated unless suggestive aspects in the history and physical
examination (H&E) or adverse prognostic histologic features are
present. Stage I is local disease, stage II is regional disease, and stage
III is distant disease.
Treatment
Initial treatment of DFSP is surgical. Because of its proclivity for
irregular and frequently deep subclinical extensions, every effort should
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. MS-2
Guidelines Index
DFSP Table of Contents
Discussion, References
Practice Guidelines
in Oncology – v.1.2010 Dermatofibrosarcoma Protuberans
®
NCCN
be made to completely remove this tumor at the time of initial therapy.
The surgical approach to DFSP must be meticulously planned. Size
and location of the tumor as well as cosmetic issues will dictate the
most appropriate surgical procedure. As noted in the algorithm
(DFSP-A), some form of complete histologic assessment of all surgical
margins before reconstruction is preferred. See NCCN Soft Tissue
Sarcoma Guidelines for principles of sarcoma surgery (SARC-C). Mohs
or modified Mohs surgery,3,4,13-20 and traditional wide excision,21
typically with 2-4 cm margins to investing fascia that are subsequently
verified to be clear by traditional pathologic examination, are all
methods to achieve complete histologic assessment.14,22 In a recent
retrospective review of 48 patients, positive margins were more
frequent with wide excision than with Mohs, but the local recurrence
rates were statistically similar (3.6% vs 0%, respectively, P = 1.0).23
Immediate reconstruction can be performed in most cases. If there is
concern that the surgical margins are not completely clear, tissue
rearrangement should be avoided, and split thickness skin grafting
(STSG) should be considered to monitor for recurrence.
DFSP is characterized by a translocation between chromosomes 17
and 22 [t(17:22)] resulting in the over expression of platelet-derived
growth factor receptor β (PDGFRB).24-26 These findings suggest that
targeting PDGF receptors may lead to the development of new
therapeutic options for DFSP. In recently published results, imatinib
mesylate, a protein tyrosine kinase inhibitor, has shown clinical activity
against localized and metastatic DFSP tumors containing t(17:22).27-30
Imatinib mesylate has recently been approved by the FDA for the
treatment of unresectable, recurrent and/or metastatic DFSP in adult
patients.31 Because tumors lacking the t(17;22) translocation may not
respond to imatinib molecular analysis of a tumor using cytogenetics
may be useful prior to the institution of imatinib therapy.
Radiation has occasionally been used as a primary therapeutic
modality for DFSP,32 but it is more commonly used as adjuvant therapy
after surgery.33-35 Postoperative radiation therapy can also be
considered for negative margins for large lesions or if there is concern
about the adequacy of the surgical margins. Postoperative radiation
therapy or imatinib mesylate should be considered for positive surgical
margins following re-resection (DFSP-2), if further resection is not
feasible (unresectable disease).
Radiation therapy, if not given previously, or imatinib mesylate should
be considered for patients with recurrent disease, if additional resection
would lead to unacceptable functional or cosmetic outcomes (DFSP-2).
Clinical trials, imatinib mesylate, chemotherapy, radiation therapy or
re-resection as feasible under specific clinical circumstances should all
be considered in the rare event of metastatic disease.
Several clinical trials are underway for the treatment of DFSP with
imatinib. To access current clinical trials, go to www.clinicaltrials.gov.
Follow-up
Finally, given the historically high local recurrence rates for DFSP,
ongoing clinical follow-up of the primary site every 6-12 months is
indicated, with re-biopsy of any suspicious regions. Although metastatic
disease is rare, a guided H&E should be performed as well, with
additional imaging studies as indicated.
Version 1.2010, 03/19/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. REF-1
Guidelines Index
DFSP Table of Contents
Discussion, References
Practice Guidelines
in Oncology – v.1.2010 Dermatofibrosarcoma Protuberans
®
NCCN
References
1. Criscione VD, Weinstock MA. Descriptive epidemiology of
dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J
Am Acad Dermatol. 2007;56:968-973.
2. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue
sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases.
Cancer. 2008;113:616-627.
3. Haycox CL, Odland PB, Olbricht SM, Casey B. Dermatofibrosarcoma
protuberans (DFSP): growth characteristics based on tumor modeling
and a review of cases treated with Mohs micrographic surgery. Ann
Plast Surg. 1997;38:246-251.
4. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic
surgery for the treatment of dermatofibrosarcoma protuberans. Results
of a multiinstitutional series with an analysis of the extent of
microscopic spread. J Am Acad Dermatol. 1997;37:600-613.
5. Vidimos AT, Helm TN, Papay FA. Dermatofibrosarcoma protuberans.
In: Cutaneous Oncology: Pathophysiology, Diagnosis, and
Management. Malden, MA: Blackwell Scientific. 1998:822-831.
6. Cribier B, Noacco G, Peltre B, Grosshans E. Stromelysin 3
expression: a useful marker for the differential diagnosis
dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad
Dermatol. 2002;46:408-413.
7. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma
from dermatofibrosarcoma protuberans: comparison with CD34 and
factor XIIIa. Hum Pathol. 2001;32:50-56.